期刊文献+

Array-ELISA法和ECLIA法测定六项肿瘤标志物的比较研究 被引量:11

Comparison research of Array-ELISA and ECLIA in determination of six tumor markers in serum
暂未订购
导出
摘要 目的分析和评价6项肿瘤标志物测定试剂盒[微阵列酶联免疫法(Array-ELISA)]在肿瘤标志物检测中的应用价值。方法采用Array-ELISA和电化学发光免疫分析法(ECLIA)检测相同标本的6项临床常见肿瘤标志物:甲胎蛋白(AFP)、癌胚抗原(CEA)、前列腺特异性抗原(PSA)、糖类抗原125(CA125)、糖类抗原199(CA199)和糖类抗原153(CA153)。采用受试者工作特征(ROC)曲线进行分析。结果 2种方法检测AFP、CEA、PSA和CA125的阳性率差异无统计学意义(P>0.05),检测CA199和CA153的阳性率差异有统计学意义(P<0.01)。2种方法对AFP、CEA、PSA、CA125和CA199的检测结果总符合率均>85%,仅CA153的总符合率为61.1%。2种方法对6项肿瘤标志物的检测结果显著相关(P<0.01),相关系数(r)为0.695~0.960。2种方法检测AFP、CEA、PSA、CA125和CA199对相关肿瘤诊断的ROC曲线下面积介于0.62~0.99之间;用Array-ELISA检测CA153对乳腺癌诊断的ROC曲线下面积低于ECLIA。结论 Array-ELISA与ECLIA对6项肿瘤标志物的检测结果均有良好一致性,可以引入Array-ELISA检测6项肿瘤标志物作为常规体检项目和筛查项目。 Objective To analyze and evaluate the clinical application of tumor marker detection kit [microarray enzyme-linked immunosorbent assay(Array-ELISA)] in determining 6 tumor markers.Methods Electro-chemiluminescence immunoassay(ECLIA) analyzer was used to detect 6 clinically common tumor markers: alpha fetoprotein(AFP),carcinoembryonic antigen(CEA),prostate specific antigen(PSA),carbohydrate antigen 125(CA125),carbohydrate antigen 199(CA199) and carbohydrate antigen 153(CA153).The receiver operating characteristic(ROC)curve was evaluated.Results There were no significant differences in the positive rates of AFP,CEA,PSA and CA125 by the 2 methods(P〉0.05),while the positive rates of CA199 and CA153 had statistical significance(P〈0.01).The determination results of AFP,CEA,PSA,CA125 and CA199 by the 2 methods showed high total coincidence rate(85%),and the total coincidence rate of CA153 was 61.1%.The correlation was significant [P〈0.01,correlation coefficient(r)=0.695-0.960],and areas under ROC curves of AFP,CEA,PSA,CA125 and CA199 were 0.62-0.99.The area under ROC curve of CA153 by Array-ELISA was lower than that of ECLIA in the diagnosis of breast carcinoma.Conclusions Both Array-ELISA and ECLIA show good coincidence in detecting the 6 tumor markers,and Array-ELISA could be introduced for clinical routine examination and screening testing of determining 6 tumor markers.
出处 《检验医学》 CAS 2012年第1期4-7,共4页 Laboratory Medicine
基金 广东省科技厅社会发展计划资助项目(2008B060600042)
关键词 微阵列酶联免疫法 电化学发光法 方法学比较 肿瘤标志物 Microarray enzyme-linked immunosorbent assay Electro-chemiluminescence immunoassay Methodology comparison Tumor marker
  • 相关文献

参考文献6

二级参考文献29

  • 1吴健民.对肿瘤标志物的再认识[J].中华检验医学杂志,2005,28(1):11-13. 被引量:116
  • 2杨美香,曲迅,孔北华.SELDI-TOF MS技术及其在卵巢癌和乳腺癌早期诊断中的应用[J].医学综述,2005,11(4):332-334. 被引量:5
  • 3李振甲,高平.标记免疫检验技术研究的新进展[J].中华医学检验杂志,1994,17(5):308-310. 被引量:8
  • 4刘小丽,李兰娟.SELDI-TOF MS技术及其在传染性疾病研究中的应用[J].国外医学(流行病学.传染病学分册),2005,32(3):149-152. 被引量:1
  • 5Gutstein HB, Morris JS, Annangudi SP, et al. Microproteomics: analysis of protein diversity in small samples [J]. Mass Spectrom Rev, 2008, 27(4) :316-330.
  • 6Von Eggeling F, Melle C, Ernst G. Microdissecting the proteome [ J ]. Proteomics, 2007, 7 (16) :2729-2737.
  • 7Bentzen SM, Buffa FM, Wilson GD. Multiple biomarker tissue microarrays: bioinformatics and practical approaches[J]. Cancer Metastasis Rev, 2008, 27 (3) :481 - 494.
  • 8PETRICOIN E F, ABDEKANI A M, HITT B A, et al. Useofpr oteomic patterns in serum to identify ovarian cancer [J] .Lancet, 2002, 359 (9306) : 572 - 577.
  • 9SAMCHEZ-CABBAYO M, ESPASA A,CHINCHILLA V, et al. New electrochermieluninescent immunoassay for the dertermination of CYRA21-1: analytical evaluation and clinical diagnostic.pcrfor-mance in urine samples of patients with Madder cancer [J]. Clin Chem, 1999,45(11): 1944.
  • 10FODINGER M, SUNDER-PLASSM ANN G, WAGNER O F. Trends in molecular diagnostics [J]. Wien Klin Wochenschr,1999, 111(8): 315- 319.

共引文献28

同被引文献92

  • 1容毓,邓粤敏.几种肿瘤标志物检测方法的进展及应用[J].实用医学杂志,2006,22(9):1094-1095. 被引量:9
  • 2戴新华,李红梅,齐韬.临床检验量值溯源及其标准物质的研究现状[J].化学分析计量,2007,16(5):7-9. 被引量:12
  • 3Predki P F, Mattoon D, Bangham R, et al. Protein microarrays: a new tool for profiling antibody cross reactivity [J]. Hum Antibodies,2005,14(1/2) :7-15.
  • 4Kirat H T, Ozturk E, Lavery I C, etal. The predictive value of preoperative carcinoembryonic antigen level in the prognosis of coloncancer[J]. AmJ Surg,2012,204(4):447 -452.
  • 5陈创,陈利琴,杨国梁,李雁.肿瘤标志物在结直肠癌诊断和监测中的价值和改进策略:130例患者的临床资料分析(英文)[J].癌症,2007,26(11):1221-1226. 被引量:33
  • 6Coughlin SS,Steven S,Ekwueme DU. Breast cancer as aglobal health concern[J]. Cancer Epidemiology, 2009, 33(5):315-318.
  • 7Hery C,Ferlay J,Boniol M,et al. Changes in breast cancerincidence and mortality in middle-aged and elderly womenin 28 countries with caucasian majority populations [J].Ann Oncol,2008,19(5) :1009-1018.
  • 8XIONG P, GAN N, CAO Y, et al. An uhrasensitive electrochemical immunosensor for alpha-fetoprotein using an envision complex-antibody copolymer as a sensitive label [ J ] . Mater, 2012, 5 (12) : 2757- 2772.
  • 9WON YS, LEE SW. Targeted retardation of hepatocarcinoma cells by specific replacement of alpha-fetoprotein RNA [ J ] . J Biotechnol, 2007, 129(4) :614-619.
  • 10MURRAY MJ, COLEMAN N. Testicular cancer: a new generation of biomarkers for malignant germ cell turnouts [J] . Nat Rev Urol, 2012, 9(6): 298- 300.

引证文献11

二级引证文献40

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部